Every letter we have printed

The archives are the good news. Where a service keeps every report it has issued and lets anybody search them, the badge becomes an index entry rather than a claim, and the whole problem changes shape. That capability exists and is barely used.

Badge and product are separated by a layer of navigation on most sites I visit. The badge sits in the footer, the product is on a different page, and the association a buyer draws between them is entirely their own work.

What worries me more than shading is selective publication. A seller who commissions four determinations and publishes the best one has not corrupted any laboratory. Every document is genuine. The set is the misrepresentation, and no laboratory is in a position to detect it.

Consider the incentive on the service. A badge is a recurring revenue line and an expiry rule reduces it. That is not corruption; it is ordinary commercial gravity, and reforms that run against gravity need somebody outside the arrangement to push them.

Stopping without telling anybody is common and it makes the observational data worse than it looks, because somebody recorded as continuing may have stopped months earlier. Persistence measured from prescription records and persistence in fact are different quantities.

Reasons given in public forums are shaped by the audience. A community that values persistence will hear fewer accounts of stopping, and a community that is sceptical will hear more. Neither is a sample of anything.

The follow-up periods in this literature are shorter than the periods people are planning for by a factor of several, and that ratio deserves to be printed rather than described. Two years of evidence against a ten-year intention is a number, not an impression.

A supply-side observation. Where somebody has settled on one source for a long commitment, a change in that source’s manufacturing is a change in their arrangement, and it happens without announcement. Your dossier work is the only place I have seen this treated as a continuity question.

Placebo arms in withdrawal designs are doing something unusual: they represent stopping, not never starting. Readers who carry an intuition from initiation trials will misread them, and the papers rarely spell out the difference.

Storage between arrival and submission is the step most blind programmes describe least. A vial that sat on a desk for a fortnight before going to the laboratory has had an experiment performed on it that nobody designed.

I have run a small blind programme for two years at my own expense. The finding that surprised me was how little variation there is between suppliers compared with the variation between lots from one supplier. That is a boring result and I suspect it is the true one.

Mechanistic plausibility is used as evidence throughout the discussion of this class, and it is the weakest form of evidence available. Where an outcome study exists it should be cited instead, and where none exists that should be said.

Nothing in receptor pharmacology predicts who will respond, and the between-individual spread in the trials is wide. Until there is a marker that identifies a responder in advance, the pharmacology explains the average and is silent about the person.

Receptor expression in cardiac tissue is limited and much of the cardiovascular effect is likely indirect. I would rather see that stated as the current reading of the evidence than see the outcome data described as though the mechanism were established.

The hindbrain and hypothalamic sites are where the appetite effect lives, and the peripheral vagal contribution is more contested than a general reader would guess from most summaries. Your account distinguishes the two, which matters because they predict different things about tolerance.

Renal expression and the natriuretic findings deserve a paragraph, given how much interest there now is in kidney outcomes. It is a genuinely separate line of work from the metabolic one and it is developing quickly.

The residual moisture point is the one I would put in bold. A cake dried to one per cent water and a cake dried to four behave entirely differently over a year at the same temperature, and the certificate reports neither. Of every determination available to this trade, water content is the cheapest and the most predictive of shelf life.

Your description of collapse is right and the consequence is worth spelling out. A collapsed cake has a lower surface area and reconstitutes more slowly, and it also indicates the product went above its collapse temperature during primary drying. It is a visible record of a process deviation, sitting in the vial where anybody can see it.

Seasonal variation makes a single documented shipment close to meaningless. A supplier’s packing that performs well in March may not in July, and any claim about cold-chain performance should be dated.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.

Angle follows length rather than preference. A short needle goes in perpendicular; a longer one into a pinched fold at an angle. Treating the two as interchangeable styles rather than as consequences of the equipment is where most of the confusion sits.

Reuse is discussed as a sterility question and is also a mechanical one. A needle point deforms on first use in a way that is visible under magnification, and the deformation is what causes the second use to be different.

Your rotation advice says site does not affect absorption in this class, and then says to rotate anyway. If absorption is unaffected, why bother?

Please keep printing the conversion in both directions. Readers can usually go from concentration to volume and stumble going back from a marking to a mass, and the second direction is the one that matters when somebody is checking what they did rather than planning it.

Nothing in this file addresses what to do when you realise mid-week that you have made an error. I gave double my dose on a Sunday and could find no guidance anywhere about what that meant.

A withdrawal design also measures the effect of the surrounding programme falling away. Participants lose the visits, the monitoring and the contact at the same moment they lose the drug, and no published design separates those.

The curves everybody reproduces are drawn from the last available observation for participants who left early, which is a specific analytical choice with a known direction of bias. Alternative analyses are usually in the appendix and rarely differ dramatically, but readers should know one was made.

Monitoring intensity almost always falls during a long stable phase, which means the period with the least data is the period lasting longest. Anybody reading a personal series should know that the flat part is flat partly because nobody was looking.

The most valuable custody artefact I have is a courier record showing a parcel held for six days at a hub in July. It explains a determination that would otherwise have looked like a manufacturing failure, and it cost nothing to obtain.

I would like to see the phrase used more carefully in this publication as well. Where the history is a courier number and a photograph, say so. Where it is a signed transfer record, say that. The reader can weigh either if they are told which they are reading.

A structural suggestion. If the services published the count of reports issued to each requester alongside the count published by that requester, the selective-publication problem would be visible without disclosing a single result. It is a number they already have.

Your taxonomy would benefit from a category for external events with no relation to the arrangement at all — a house move, a family illness, a period of travel. They are common, they are not failures of anything, and they are currently distributed across every other category.

A short letter to make one point. Nobody in this area distinguishes between stopping the substance and stopping the monitoring, and the second is at least as consequential. People who continue without measuring anything have made a different decision from people who stopped.

Light exposure is trivially controllable and almost never controlled. A clear vial on a shelf near a window is running a photostability study nobody designed, and the effect is real for several residue types.

Adsorption to the container is under-appreciated. At low concentrations a meaningful fraction of peptide can be lost to the glass or the plastic within hours, which looks exactly like degradation and is not. It is also the reason a dilute working solution behaves worse than a concentrated one.

Parcel 7 reached thirty-eight degrees for nearly four hours and you then tell readers not to worry unduly. I accept the solid-state argument. I would still like to know what the material looked like on analysis, and your article does not say.

The last mile is the part nobody controls and the part that fails. A parcel can travel refrigerated for six thousand miles and then sit in a delivery van in July for eleven hours, and the pack was specified for the journey the shipper planned rather than the one that happened.

Where a subject is absent from every certificate, buyers infer that it does not matter. Silence is read as reassurance, which is the most consequential property of an absence and the least intended.

Community discussion is dominated by what can be verified cheaply, and verification cost determines which topics are live. This one has no cheap verification available to an individual, so it does not become a topic.